A phase I study of nimotuzumab plus docetaxel in chemotherapy- refractory/resistant patients with ad

• 作 者: Jun Zhao Minglei Zhuo Zhijie W
• 机 构: DepartmentsofThoracicMedicalOncology
• 出 处: 中国癌症研究：英文版
• 发表日期: 2016年1期
• 关键词: 非小细胞肺癌 患者 单抗 晚期 化疗 表皮生长因子受体 EGFR 中性粒细胞 Nimotuzumab docetaxel non-small-cell lung
• 基金项目: Acknowledgements We thank all the physicians, nurses, and patients who participated in this study.

Background: To determine the safety and therapeutic efficacy of nimotuzumab(h-R3) combined with docetaxel in advanced non-small-cell lung cancer(NSCLC) patients who have failed to respond to prior first-line chemotherapy.Methods: In this single-center, op